Halozyme (HALO) Q2 FY26 earnings call

Halozyme delivered an exceptionally strong second quarter, driven by record ENHANZE royalty revenue growth and significant new collaboration agreements for both ENHANZE and Hypercon. The company is successfully diversifying its revenue streams with multiple new product launches and expanding its platform into new therapeutic modalities like ADCs and nucleic acids, reinforcing its long-term growth trajectory and raising full-year guidance.